0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%
Last update at 2024-12-19T16:38:00Z
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design
Wed 16 Oct 24, 01:00 PMUK Value Stocks That Might Be Priced Below Intrinsic Estimates In October 2024
Wed 16 Oct 24, 06:04 AMShould You Consider Adding Smith & Nephew plc (SNN) to Your Portfolio?
Mon 14 Oct 24, 01:26 PMSNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
Fri 11 Oct 24, 01:15 PMSmith & Nephew (LON:SN.) May Have Issues Allocating Its Capital
Thu 26 Sep 24, 11:22 AMSNN Stock Rises on the Completion of First Case With CATALYSTEM System
Fri 20 Sep 24, 03:48 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 235.00M | 586.00M | 246.00M | 743.00M | 781.00M |
| Minority interest | - | - | - | - | - |
| Net income | 223.00M | 524.00M | 448.00M | 600.00M | 663.00M |
| Selling general administrative | 2880.00M | 2720.00M | 2562.00M | 2693.00M | 367.00M |
| Selling and marketing expenses | 2066.00M | 2013.00M | 1773.00M | 1911.00M | 1820.00M |
| Gross profit | 3675.00M | 3669.00M | 3164.00M | 3800.00M | 3606.00M |
| Reconciled depreciation | 628.00M | 581.00M | 562.00M | 502.00M | 435.00M |
| Ebit | 315.00M | 593.00M | 295.00M | 815.00M | 852.00M |
| Ebitda | 943.00M | 1172.00M | 904.00M | 1326.00M | 1287.00M |
| Depreciation and amortization | 628.00M | 579.00M | 609.00M | 511.00M | 435.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 315.00M | 593.00M | 295.00M | 815.00M | 1006.00M |
| Other operating expenses | 4765.00M | 4619.00M | 4265.00M | 4323.00M | 3898.00M |
| Interest expense | 80.00M | 80.00M | 62.00M | 65.00M | 71.00M |
| Tax provision | 12.00M | 62.00M | -202.00000M | 143.00M | 118.00M |
| Interest income | 14.00M | 6.00M | 6.00M | 10.00M | 8.00M |
| Net interest income | -74.00000M | -91.00000M | -63.00000M | -73.00000M | -71.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 12.00M | 62.00M | -202.00000M | 143.00M | 118.00M |
| Total revenue | 5215.00M | 5212.00M | 4560.00M | 5138.00M | 4904.00M |
| Total operating expenses | 3225.00M | 3076.00M | 2869.00M | 2985.00M | 2600.00M |
| Cost of revenue | 1540.00M | 1543.00M | 1396.00M | 1338.00M | 1298.00M |
| Total other income expense net | -80.00000M | -7.00000M | -49.00000M | -72.00000M | -225.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 223.00M | 524.00M | 448.00M | 600.00M | 663.00M |
| Net income applicable to common shares | 223.00M | 524.00M | 448.00M | 600.00M | 663.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 9966.00M | 10920.00M | 11012.00M | 9299.00M | 8059.00M |
| Intangible assets | 1236.00M | 1398.00M | 1486.00M | 1567.00M | 1210.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1301.00M | 1290.00M | 1211.00M | 1328.00M | 1317.00M |
| Total liab | 4707.00M | 5352.00M | 5733.00M | 4158.00M | 3185.00M |
| Total stockholder equity | 5259.00M | 5568.00M | 5279.00M | 5141.00M | 4874.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 457.00M | 544.00M | 329.00M | 446.00M | 224.00M |
| Common stock | 175.00M | 177.00M | 177.00M | 177.00M | 177.00M |
| Capital stock | 175.00M | 177.00M | 177.00M | 177.00M | 177.00M |
| Retained earnings | 5026.00M | 5225.00M | 4958.00M | 4849.00M | 4625.00M |
| Other liab | 280.00M | 373.00M | 692.00M | 619.00M | 419.00M |
| Good will | 3031.00M | 2989.00M | 2928.00M | 2789.00M | 2337.00M |
| Other assets | 330.00M | 398.00M | 368.00M | 291.00M | 234.00M |
| Cash | 350.00M | 1290.00M | 1762.00M | 277.00M | 365.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1715.00M | 2131.00M | 1688.00M | 1564.00M | 1465.00M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 2522.00M | 2049.00M | 1928.00M | 1770.00M | 1100.00M |
| Short term debt | 160.00M | 491.00M | 337.00M | 72.00M | 164.00M |
| Short long term debt | 111.00M | 435.00M | 279.00M | 26.00M | 164.00M |
| Short long term debt total | 2872.00M | 3339.00M | 3690.00M | 2047.00M | 1465.00M |
| Other stockholder equity | 58.00M | 166.00M | 144.00M | 115.00M | 72.00M |
| Property plant equipment | 1455.00M | 1513.00M | 1449.00M | 1323.00M | 1062.00M |
| Total current assets | 3856.00M | 4424.00M | 4664.00M | 3219.00M | 3077.00M |
| Long term investments | - | - | - | 110.00M | 139.00M |
| Net tangible assets | 992.00M | 1181.00M | 865.00M | 785.00M | 1327.00M |
| Short term investments | - | -182.00000M | -133.00000M | -106.00000M | - |
| Net receivables | 1264.00M | 1290.00M | 1106.00M | 1227.00M | 1211.00M |
| Long term debt | 2565.00M | 2707.00M | 3207.00M | 1851.00M | 1301.00M |
| Inventory | 2205.00M | 1844.00M | 1691.00M | 1614.00M | 1395.00M |
| Accounts payable | 1098.00M | 1096.00M | 1022.00M | 1046.00M | 854.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -2303.00000M | -2034.00000M | -1821.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 177.00M | 177.00M | 177.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | -157.00000M | -189.00000M | -214.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 211.00M | 15.00M | 33.00M | 35.00M | 247.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6110.00M | 6496.00M | 6348.00M | 6080.00M | 4982.00M |
| Capital lease obligations | 196.00M | 197.00M | 204.00M | 170.00M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -472.00000M | 2.00M | 7.00M | 26.00M | -2.00000M |
| Change to liabilities | -25.00000M | 82.00M | -103.00000M | 201.00M | 71.00M |
| Total cashflows from investing activities | -472.00000M | -691.00000M | -606.00000M | -1251.00000M | -378.00000M |
| Net borrowings | -450.00000M | -326.00000M | 1490.00M | 379.00M | -7.00000M |
| Total cash from financing activities | -926.00000M | -645.00000M | 1164.00M | 7.00M | -371.00000M |
| Change to operating activities | - | -150.00000M | 1.00M | -4.00000M | -35.00000M |
| Net income | 235.00M | 586.00M | 246.00M | 743.00M | 663.00M |
| Change in cash | -941.00000M | -466.00000M | 1494.00M | -76.00000M | 178.00M |
| Begin period cash flow | 1285.00M | 1751.00M | 257.00M | 333.00M | 155.00M |
| End period cash flow | 344.00M | 1285.00M | 1751.00M | 257.00M | 333.00M |
| Total cash from operating activities | 468.00M | 877.00M | 935.00M | 1168.00M | 931.00M |
| Issuance of capital stock | 6.00M | 14.00M | 11.00M | 11.00M | 13.00M |
| Depreciation | 628.00M | 581.00M | 596.00M | 518.00M | 435.00M |
| Other cashflows from investing activities | - | - | -163.00000M | -843.00000M | -31.00000M |
| Dividends paid | 327.00M | 329.00M | 328.00M | 318.00M | 321.00M |
| Change to inventory | -407.00000M | -151.00000M | -45.00000M | -204.00000M | -152.00000M |
| Change to account receivables | -103.00000M | -81.00000M | 209.00M | 30.00M | -108.00000M |
| Sale purchase of stock | -158.00000M | -59.00000M | -16.00000M | -63.00000M | -48.00000M |
| Other cashflows from financing activities | 434.00M | -4.00000M | 1902.00M | 1242.00M | 386.00M |
| Change to netincome | 232.00M | -78.00000M | -120.00000M | 49.00M | 65.00M |
| Capital expenditures | 358.00M | 408.00M | 443.00M | 408.00M | 347.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -535.00000M | -150.00000M | 61.00M | 27.00M | -189.00000M |
| Stock based compensation | 40.00M | 41.00M | 26.00M | 32.00M | 35.00M |
| Other non cash items | 100.00M | 74.00M | 56.00M | 55.00M | -13.00000M |
| Free cash flow | 110.00M | 469.00M | 492.00M | 760.00M | 584.00M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SN Smith & Nephew PLC |
-3.4 0.35% | 977.20 | 53.70 | 14.27 | 1.75 | 2.26 | 2.21 | 13.21 |
| MXCT MaxCyte Inc |
-23.0 6.65% | 323.00 | - | - | 10.41 | 2.15 | 6.75 | -6.5763 |
| NIOX NIOX Group PLC |
1.00 1.61% | 63.00 | 32.00 | 20.75 | 7.92 | 3.40 | 7.31 | 28.40 |
| EKF EKF Diagnostics Holdings Plc |
-1.1 4.38% | 24.00 | - | - | 2.40 | 2.09 | 2.25 | -19.3996 |
| CREO Creo Medical Group PLC |
0.75 4.62% | 17.00 | - | - | 4.53 | 1.91 | 3.91 | -4.68 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Building 5, Watford, United Kingdom, WD18 8YE
| Name | Title | Year Born |
|---|---|---|
| Ms. Anne-Francoise Nesmes | CFO & Exec. Director | 1972 |
| Dr. Deepak S. Nath Ph.D. | CEO & Director | 1973 |
| Mr. Paul Connolly | Pres of Global Operations | 1968 |
| Mr. Andrew Swift | VP of Investor Relations | NA |
| Ms. Helen Barraclough | Group Gen. Counsel, Company Sec. & Director | 1979 |
| Ms. Alison Parkes | Chief Compliance Officer | 1972 |
| Mr. Joe Metzger | Sr. VP of Marketing Services & Communications | NA |
| Ms. Elga Lohler | Chief HR Officer | 1968 |
| Mr. Philip G. Cowdy | Chief Bus. Devel. & Corp. Affairs Officer | 1967 |
| Mr. Bradley Cannon | Pres of Orthopaedics, Sports Medicine & ENT and Americas | 1968 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...